3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
10
Neoplasms
4
Neoplasm Metastasis
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Kaposi
1
Sarcoma
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms by Site
1
Multiple Myeloma
1
Meningioma
1
Lymphoma, Non-Hodgkin
1
Low Grade Serous Ovarian Carcinoma
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Liposarcoma
1
Leiomyosarcoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Hemangiosarcoma
1
HR+/HER2- Breast Cancer
1
Glioma
1
Interventions
Letrozole
4
Fulvestrant
2
Anastrozole
2
toripalimab
1
ribociclib
1
palbociclib
1
exemestane
1
elacestrant
1
disitamab vedotin
1
abemaciclib
1
Paclitaxel
1
Lead
1
Injections
1
Goserelin
1
AZD9833
1
AZD5305
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Breast Cancer
×
abemaciclib
×
30 days
×
Clear all
NCT06380751
2026-05-15
EvoPAR-BR01
AstraZeneca
Phase 3
Recruiting
500 enrolled